McRae Capital Management
VRTX icon

McRae Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

McRae Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16.7M Sell
31,920
-1,271
-4% -$651K 3.09% 7
2026
Q2 		$16.5M Sell
33,191
-932
-3% -$413K 3.24% 12
2026
Q1 		$15.2M Sell
34,123
-1,435
-4% -$669K 3.16% 12
2025
Q4 		$16.1M Buy
35,558
+2,399
+7% +$1.03M 3.29% 13
2025
Q3 		$13M Buy
33,159
+2,706
+9% +$1.13M 2.58% 17
2025
Q2 		$13.6M Buy
30,453
+125
+0.4% +$57.6K 2.78% 16
2025
Q1 		$14.7M Sell
30,328
-750
-2% -$350K 3.1% 12
2024
Q4 		$12.5M Sell
31,078
-802
-3% -$372K 2.45% 19
2024
Q3 		$14.8M Sell
31,880
-1,640
-5% -$788K 2.89% 15
2024
Q2 		$15.7M Sell
33,520
-420
-1% -$182K 3.58% 11
2024
Q1 		$14.2M Sell
33,940
-785
-2% -$332K 3.11% 15
2023
Q4 		$14.1M Sell
34,725
-543
-2% -$201K 3.53% 12
2023
Q3 		$12.3M Sell
35,268
-312
-0.9% -$109K 3.63% 11
2023
Q2 		$12.5M Buy
35,580
+231
+0.7% +$77.8K 3.56% 12
2023
Q1 		$11.1M Sell
35,349
-410
-1% -$123K 3.21% 14
2022
Q4 		$10.3M Sell
35,759
-606
-2% -$185K 3.02% 14
2022
Q3 		$10.5M Sell
36,365
-130
-0.4% -$37.4K 3.2% 13
2022
Q2 		$10.3M Buy
36,495
+7,995
+28% +$2.14M 2.79% 15
2022
Q1 		$7.44M Buy
+28,500
New +$6.76M 1.68% 26

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

McRae Capital Management's VRTX Position: Q3 2026 in Review

McRae Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q3 2026, selling an estimated $651K and leaving 31,920 shares worth $16.7M. The position accounts for 3.09% of the portfolio, ranked #7.

McRae Capital Management first reported a position in VRTX in Q1 2022 and has held it in 19 quarters since. 1,069 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • McRae Capital Management held 31,920 shares of Vertex Pharmaceuticals worth $16.7M as of Q3 2026.
  • McRae Capital Management sold 1,271 Vertex Pharmaceuticals shares in Q3 2026, an estimated $651K.
  • Vertex Pharmaceuticals made up 3.09% of McRae Capital Management's portfolio in Q3 2026, its #7 holding.
  • McRae Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • 1,069 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on McRae Capital Management's 13F filing for Q3 2026, filed 15 Oct 2026.